AlphAIAlphAI — Financial news for AI agents
investing.comOCT 61 min read$KMDA

Kamada launches two biosimilar products in Israel

Kamada Ltd. launched two biosimilar products in Israel: Ustekinumab-Kamada and Enoxaparin-Kamada. The company expects its biosimilar portfolio to generate $4M in 2026, growing to $10M by 2028, and $20M-$25M by 2030. Kamada plans to add at least two more biosimilar products in 2027.

Original reporting
investing.com
Published Oct 6, 2026, 11:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$KMDA
Neutral
medium confidence
Mentioned
$KMDA
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KMDANeutralLow
01

Why it matters

The two product launches provide new revenue streams and signal growth ambition, but the modest financial magnitude limits immediate market impact.

02

Market read

Primary disclosure of a product launch for a micro‑cap biotech; modest upside potential but limited broader market relevance.

03

What to watch

Potential future pipeline expansion and regional pricing advantages could enhance long‑term value.

Relevance 6/10Novelty 6/10Timing: today

Background

Kamada Ltd. (NASDAQ:KMDA) is a biopharmaceutical company focused on biosimilars and plasma‑derived products, operating plasma collection centers in Texas.

Company-level read

Ticker impact

$KMDANeutralMedium confidence
Context

Kamada announced the commercial launch of two new biosimilar products in Israel, providing fresh revenue guidance for 2026-2028.

Expected impact

potential modest upside as investors price in new biosimilar sales

Evidence & confidence

New product introductions are positive catalysts, but projected sales are relatively small ($4‑10M) for a micro‑cap, limiting impact.

Market effects

Sector

Expands the Israeli biosimilar market, modestly increasing competition among specialty biologics.

Regional

Adds to Israel's domestic biotech pipeline, but limited global effect.

Global

Low; impact confined to Kamada and regional biosimilar landscape.

Counterpoint

What could challenge this read

Given the small revenue size and competitive biosimilar space, the launch may not move the stock significantly.

Key entities

  • Company
    Kamada Ltd.

    Biopharma developing biosimilars, listed on NASDAQ under KMDA.

Read at source← All news

Related articles

AUG 19
$KMDAMed

Kamada (KMDA) Q2 2026 Earnings Call Transcript

Kamada reported Q2 2026 earnings with record revenues of $54.9M (+23% YoY) and adjusted EBITDA of $14.1M (+29% YoY). The company reiterated its 2026 guidance of $200M-$205M in revenues and $50M-$53M in adjusted EBITDA. Growth is driven by existing products, with plans to accelerate through acquisitions and expanded distribution. Key products like KEDRAB and GLASSIA showed strong demand, and the company expects plasma sales to begin by year-end.

yahoo.com2 min
AUG 12
$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

yahoo.com6 min
AUG 12
$KMDAHighAI 9/10

Kamada Ltd.: Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Gui

Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.

finanznachrichten.de6 min
AUG 12
$KMDAMed

KAMADA LTD (KMDA): Financial results for H1 2026

KAMADA LTD (KMDA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance ● Record-High First Half Revenues of $100.2 Million, up 13% Year-over-Year

SEC EDGAR 6-K2 min
JUL 20
$KMDAMedAI 8/10

Kamada jumps on $50m source plasma deal

Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.

globes.co.il2 min
OCT 24
$BAMed

Reuters Reports Boeing 777F Halt in Vaero Dispute

Boeing's 777 Freighter production was halted for nearly two months due to a dispute with supplier Vaero, according to Reuters. The disruption also affected 767 output, including freighters and KC-46 tankers. Boeing alleged daily costs of up to $6.5m. Emirates ordered five additional 777Fs in October 2024. Boeing declined to comment, and Vaero and FedEx did not respond to requests.

airwaysmag.com2 min